Although the impact of biosimilars in the U.S. will be gradual, drug company investors should still be wary. The initial stakes are low for the imminent launch of the first U.S. biosimilar drug, but shouldn’t be expected to stay that way. Read more here. (Source: Charley Grant, The Wall Street Journal, 9/3/15)
You are here: / / Is Big Pharma Ready for the Biosimilar Invasion?